Trials / Completed
CompletedNCT00047762
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
Open-Label, Multicenter, Dose-Escalation Study in Subjects w/Advanced Colorectal Cancer to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tarceva in Combination w/5-Fluorouracil, Leucovorin, and Irinotecan and of Bevacizumab in Combination w/Tarceva, 5-Fluorouracil, Leucovorin, and Irinotecan
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib (aka Tarceva or OSI-774) | |
| DRUG | Bevacizumab (aka Avastin or Rhu MAb VEGF) |
Timeline
- Start date
- 2002-10-01
- First posted
- 2002-10-18
- Last updated
- 2005-06-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00047762. Inclusion in this directory is not an endorsement.